Abstract library

11 results for "Valls".
#2990 Pitfalls in Glucagon-Like Peptide-1 Receptor Imaging
Introduction: Physiological pancreatico-duodenal DOTA-Exendin-4 uptake in the Brunner’s glands of the proximal duodenum occurs in Glucagon-like peptide-1 receptor (GLP-1R) imaging and is a known potential pitfall.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Antwi Antwi
#2743 Mimics of Neuroendocrine Neoplasms Identified in a Single Consultation Center between 2009 and 2019
Introduction: Immunohistochemical expression of synaptophysin (SYN), chromogranin (CgA) and cytokeratin are essential for diagnosis of NENs. Non-NENs, however, may occasionally also express NE-markers and cytokeratin and cause diagnostic difficulties.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Atsuko Kasajima
#2824 Patient and Nurse Satisfaction with the New Lanreotide Autogel Pre-Filled Syringe in Neuroendocrine Tumors (NET): A Prospective Study (SONATE)
Introduction: A new syringe (NS) for the delivery of lanreotide autogel was approved in Oct 2018 in France. The NS includes updated features (larger flanges, more robust plunger) intended to ease the injection.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr. Olivier Mir
Authors: Walter T, Eskenazi M, Rama N, Gueguen D, ...
#729 Neuroendocrine Neoplasms of the Ampulla of Vater: Clinicopathological Analysis of Nine Cases
Introduction: Neuroendocrine neoplasms (NEN) of the ampulla of Vater (AV) are rare and heterogeneous and little is known about their biological behavior.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Luis Perez-Casanova
#971 Well-differentiated Pancreatic Neuroendocrine Tumors: Prognostic Significance of Pathological Parameters
Introduction: Well-differentiated (WD) pancreatic neuroendocrine tumors (pNET) are uncommon neoplasms and one challenge lies in predicting tumor behavior and managing these patients.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Luis Pérez-Casanova
#975 Electron Microscopy of Pancreatic Beta Cell Neuroendocrine Tumors (NETs) in Multiple Endocrine Neoplasia Type 1 (MEN1) Knockout Mice Reveal an Adenomatous Phenotype with Depletion of Insulin Granules and Increased Mitochondrial Content
Introduction: Insulinomas are β cell neuroendocrine tumors (NETs) that secrete insulin, and ~4% of insulinoma patients have multiple endocrine neoplasia type 1 (MEN1). One in ten MEN1 patients present with an insulinoma. Previous reports describe insulinomas as possibly having typical granules (46.4%) or atypical smaller granules (34.3%), both associated with adenomas, or agranular cells (14.3%) associated with carcinomas. MEN1 knockout (Men1+/-) mice develop pancreatic NETs that are mostly insulinomas, and their ultrastructural phenotype is unknown. We hypothesized that these may resemble the adenoma phenotype with atypical granules.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Gerard V Walls
Authors: Walls G V, Clark A, Thakker R, ...
Keywords: GEP-NET
#1394 The Difficulties of Response Assessment After Peptide Receptor Radionucleotide Therapy (PRRT): An Unusual Case of Symptomatic Pseudoprogression
Introduction: In previous studies patient symptoms, biochemistry (including chromogranin A) and imaging using RECIST criteria have been used to assess tumour response to PRRT.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Clinical cases/reports
Presenting Author: Dr Rahul Ladwa
Authors: Ladwa R, Lyle M, Wyld D, Burge M, ...
#1644 Pitfalls in the Response Evaluation after Peptide Receptor Radionuclide Therapy with [177Lu-DOTA0,Tyr3]Octreotate
Introduction: PPRT with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic GEPNETs
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Tessa Brabander
#1741 Complete Remission of Hepatic Metastasis after Total Gastrectomy for a Gastric Carcinoid Tumor Type 1: A Case Report
Introduction: A 58-year-old woman was referred to our hospital for hepatic lesions and thickening of the walls of the stomach detected by abdominal CT scan. An upper GI endoscopy showed a lesion of the body of the stomach and the histopathologic exam documented a well differentiated NET. 68Ga-DOTATOC PET showed pathologic uptake in the stomach and in the liver (3 lesions). Circulating chromogranin A and gastrin were 596 ng/ml and 2283 pg/ml respectively
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: Valeria Smiroldo
#2018 Ex Vivo Activity of Cytotoxic Drugs and Targeted Agents in Small Intestinal Neuroendocrine Tumors
Introduction: Small Intestinal Neuroendocrine Tumours (SI-NETs) are considered to be generally resistant to systemic treatment. To date predictive markers for drug activity are lacking.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Kosmas Daskalakis